Piper Jaffray Announces Ticker Symbol Change to PIPR

MINNEAPOLIS--(BUSINESS WIRE)-- Piper Jaffray Companies (NYSE: PJC), a leading investment bank and institutional securities firm, today announced that following the completion of its merger with Sandler O’Neill + Partners, L.P. it will trade on the NYSE under the ticker symbol “PIPR”. As previously announced, to reflect the combination of the two companies, Piper Jaffray Companies will be renamed Piper Sandler Companies. The change in name to Piper Sandler Companies and the new ticker symbol will both become effective following the merger, which is expected to close on January 3, 2020.

ABOUT PIPER JAFFRAY
Piper Jaffray Companies (NYSE: PJC) is a leading investment bank and institutional securities firm driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Jaffray & Co., member SIPC and FINRA; in Europe through Piper Jaffray Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Jaffray Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Asset management products and services are offered through four separate investment advisory affiliates. U.S. Securities and Exchange Commission (SEC) registered Piper Jaffray Investment Management LLC, PJC Capital Partners LLC and Piper Jaffray & Co., and Guernsey-based Parallel General Partners Limited, authorized and regulated by the Guernsey Financial Services Commission.

Follow Piper Jaffray: LinkedIn | Facebook | Twitter

Since 1895. © 2019 Piper Jaffray Companies, 800 Nicollet Mall, Suite 1000, Minneapolis, Minnesota 55402-7036

View source version on businesswire.com: https://www.businesswire.com/news/home/20191213005478/en/

Pamela Steensland
Tel: 612 303-8185
[email protected]

Source: Piper Jaffray Companies

You May Also Be Interested In

• ZenaTech signs offers to acquire surveying firms in U.S., Canada, Australia
• SEC clears S-4 for Olin and Huntsman all-stock merger
• Hemab shares sutacimig Phase 2 data at ISTH 2026 congress